The innovative biodrying-enhanced composting (BEC) process produces highly matured fertilizer within 10 d. To clarify the biodrying-accelerated humification mechanism, structural and molecular variations in humic acid (HA) during BEC were compared to those during 16-d bioaugmented mechanical composting without biodrying. Results showed that BEC produced HA with significantly higher aromaticity and molecular size (p < 0.01). More aromatic skeletons, mainly from biodrying-enhanced lignin decomposition (p < 0.05), contributed to HA aromatization. Reactive phenolic hydroxyls on these skeletons facilitated the binding of other humic precursors, promoting HA elongation. Microbial analysis indicated that Bacillus, Sinibacillus, and Issatchenkia, enriched by drastic heating and dehydration during days 0-3, participated in lignin decomposition. Saccharomonospora, Georgenia, Oceanobacillus, Nigrospora, Kluyveromyces, and Aspergillus contributed to HA elongation during the maturation phase (days 3-9). This study's findings that biodrying enhanced lignin-related humification pathways by enriching functional microorganisms provides a theoretical foundation for further improving compost humification efficiency.

01 Dec 2024·Journal of Hazardous Materials

Will the removal of carbon, nitrogen and mixed disinfectants occur simultaneously: The key role of heterotrophic nitrification-aerobic denitrification strain

Article

Author: Xie, Tian ; Zhang, Yi ; Gao, Jingfeng ; Guo, Yi ; Wang, Qian ; An, Jiawen

The capacity and mechanism of heterotrophic nitrification-aerobic denitrification (HNAD) strain (H1) to remove carbon, nitrogen, disinfectants chloroxylenol (PCMX) and benzethonium chloride (BEC) were investigated in this study. PCMX was removed via metabolism and chemical oxygen demand co-metabolism process. BEC was eliminated through bacterial adsorption, which greatly inhibited the removal of other pollutants. Carbon source optimization tests revealed that glucose was the optimal carbon source for co-removal of pollutants under mixed disinfectants circumstances (PCMX + BEC). Comparing the groups without (G1) and with disinfectants (G2), the content of extracellular polymeric substances was higher, and hydrophobicity was enhanced under the hazardous conditions of G2. All the nitrogen metabolism functional genes in G2 were up-regulated, and the electron transport system activity was also improved. At the same time, G2 had lower reactive oxygen species content, which reduced the probability of resistance genes dissemination, but the abundance of most quantified resistance genes was elevated in G2. Toxicity assessment assays found a dramatic reduction in the virulence of G2's effluent compared with the mixed disinfectants. The results confirmed that H1 strain could be used to treat the disinfectant-containing wastewater, which may aid in the application of HNAD process.

01 Nov 2024·CHEST

Rethinking Blood Eosinophils for Assessing Inhaled Corticosteroids Response in COPD

Article

Author: Sivapalan, Pradeesh ; Vestbo, Jørgen ; Mathioudakis, Alexander G ; Jensen, Jens-Ulrik Stæhr ; Singh, Dave ; Bate, Sebastian

BACKGROUNDThe varied treatment response to inhaled corticosteroids (ICS) in patients with COPD and the associated increased risk of pneumonia necessitate a personalized ICS therapeutic approach. This is informed by blood eosinophil count (BEC), which predicts ICS treatment response. However, BEC appears to change in response to ICS treatment.RESEARCH QUESTIONDoes (1) BEC measured on ICS treatment (2) BEC measured off ICS treatment, or (3) the change in BEC during ICS treatment best predict treatment response to ICS in COPD?STUDY DESIGN AND METHODSThe Fluticasone Salmeterol on COPD Exacerbations Trial (FLAME), a 52-week, double-blind randomized controlled trial compared long-acting beta-2 agonists (LABAs)/long-acting muscarinic antagonists (LAMAs) with LABA/ICS. Corticosteroids were prohibited during a 4-week run-in period. We chose patients previously on ICS, thereby allowing BEC before and after the run-in period to represent BEC on and off ICS, respectively. In this post hoc analysis, we revisited outcome data, exploring how the three BEC biomarkers interacted with treatment response to the ICS-containing regimen.RESULTSOur study showed that LABA/LAMA combination was superior, or at least noninferior, to LABA/ICS in curbing exacerbations for most FLAME participants. However, higher BEC off ICS, higher BEC on ICS, and significant BEC suppression during ICS treatment corresponded to superior response to LABA/ICS in terms of exacerbation rate, time to first exacerbation, and time to first pneumonia. In a subgroup, including 9% of participants, BEC changed significantly during ICS treatment (≥ 200 cells/μL), and higher BEC on ICS did not predict ICS treatment response. For these patients, BEC off ICS and BEC change proved more predictive. Excess pneumonia risk associated with ICS appeared to be confined to patients who do not benefit from this treatment. BEC was not predictive of treatment effects on lung function and health status.INTERPRETATIONThis exploratory analysis advocates preferentially using BEC off ICS or BEC change during ICS treatment for guiding ICS treatment decisions. BEC measured on ICS is less predictive of treatment response.CLINICAL TRIAL REGISTRATIONClinicalTrials.gov; No.: NCT01782326; URL: www.CLINICALTRIALSgov.

100 Deals associated with Aranidipine

External Link

KEGG	Wiki	ATC	Drug Bank
D01562	Aranidipine	C08CA	DB09229

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Angina Pectoris	JP	-	27 Apr 1997
Hypertension	-	-	01 Jan 1996

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis